Given the potential role of the JAK2 mutation in this SCLS case, our concerns remain regarding the management of our patient with a JAK2 inhibitor, as we are uncertain about potential medication-induced exacerbations. Here, JAK2 is linked to Systemic capillary leak syndrome.